多发性骨髓瘤市场 - KOL的考察

本报告提供多发性骨髓瘤市场相关调查分析，对已上市的治疗方法和开发平台有的治疗方法的KOL的考察。

目录

摘要整理

现在与未来的治疗流程

调查目的

单株抗体(mAb)

• 已通过核准的医药品
  • Darzalex（daratumumab；杨森）
  • Sarclisa（isatuximab；赛诺菲）
• 正在研究药物
  • Modakafusp alfa（TAK-573；武田）

免疫调节药物 (IMiD)

• 正在研究药物
  • 伊贝多胺（CC-220；BMS）和美齐格多胺（CC-92480；BMS）

细胞凋亡刺激剂

• 正在研究药物
  • Venetoclax（Venclexta/Venclyxto；艾伯维/基因泰克）

CAR T 细胞疗法

• 核准的治疗方法
  • Abecma（idecabtagene vicleucel；BMS/2seventy bio）
  • Carvykti（ciltacabtagene autoleucel；Janssen/Legend Biotech）
• 管道疗法
  • 新型 CAR T 细胞疗法（Gilead [Kite]/Arcellx 的 CART-ddBCMA；BMS 的 BMS-986393）

双特异性抗体

• 核准的药品
  • Tecvayli（teclistamab；杨森）
• 正在研究药物
  • 针对 BMCA 的双特异性抗体（辉瑞的 elranatamab；再??生元的 linvoseltamab；艾伯维的 ABBV-383）
  • 具有新标靶的双特异性抗体（杨森的 talquetamab；罗氏的 cevostamab）

未来治疗趋势

• 重要考虑因素摘要

附录

KOL突发新闻

In which frontline settings is Janssen's widely-used anti-CD38 mAb Darzalex expanding and what factors could increase the prospects of Sanofi's competitor Sarclisa? CAR-T cell therapies such as Janssen's Carvykti may be achieving unprecedented response rates but are hampered by concerns about durability and access. How might readily available bispecific antibody Tecvayli capitalise? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

• 31 Aug 2023 KOL Bulletin -- Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs)

• Approved drugs
  • Darzalex (daratumumab; Janssen)
  • Sarclisa (isatuximab; Sanofi)
• Pipeline drugs
  • Modakafusp alfa (TAK-573; Takeda)

Immunomodulatory drugs (IMiDs)

• Pipeline drugs
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

Apoptosis stimulants

• Pipeline drugs
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Genentech)

CAR T-cell therapies

• Approved therapies
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio)
  • Carvykti (ciltacabtagene autoleucel; Janssen/Legend Biotech)
• Pipeline therapies
  • Novel CAR T-cell therapies (Gilead [Kite]/Arcellx's CART-ddBCMA; BMS' BMS-986393)

Bispecific antibodies

• Approved drugs
  • Tecvayli (teclistamab; Janssen)
• Pipeline drugs
  • BMCA-targeting bispecific antibodies (Pfizer's elranatamab; Regeneron's linvoseltamab; AbbVie's ABBV-383)
  • Bispecific antibodies with novel targets (Janssen's talquetamab; Roche's cevostamab)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins